Coronary Artery Disease Clinical Trial
— BIOFLOW-VIIOfficial title:
BIOTRONIK - A Prospective Multicenter Study to Confirm the SaFety and Effectiveness of the Orsiro SiroLimus Eluting Coronary Stent System in the Treatment Of Subjects With up to Three De Novo or Restenotic Coronary Artery Lesions - VII
Verified date | May 2024 |
Source | Biotronik, Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
The objective of this post-approval study is to confirm that the clinical performance of the Orsiro stent in a real-world setting is similar to the clinical performance observed for Orsiro in the BIOFLOW-V Investigational Device Exemption pivotal trial, as a condition of the US Food and Drug Administration (FDA) approval (P170030).
Status | Active, not recruiting |
Enrollment | 556 |
Est. completion date | January 2026 |
Est. primary completion date | January 12, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Subject is =18 years of age. 2. Subject was an acceptable candidate for treatment with a drug eluting stent at the qualifying index procedure, in accordance with the applicable guidelines on percutaneous coronary interventions and manufacturer's Instructions for Use. 3. Subject received at least one Orsiro stent during an index procedure occurring within 24 hours prior to informed consent, as assessed by the end time of procedure. If more than one stent was implanted during the index procedure, all stents were Orsiro stents. 4. Subject is eligible for dual antiplatelet therapy (DAPT) treatment with aspirin plus either clopidogrel, prasugrel, ticagrelor or ticlopidine. 5. Subject is willing to comply with study follow-up requirements. 6. Subject has provided written informed consent as approved by the Institutional Review Board (IRB) of the respective clinical site. Legally authorized representatives are not allowed to consent on a subject's behalf. Each target lesion/vessel must have met all of the following angiographic criteria from the index procedure for the subject to be eligible for the trial: 1. Subject has up to three target lesions in up to two separate target vessels (two target lesions in one vessel and one target lesion in a separate vessel). 2. Target lesion must be de novo or restenotic lesion in native coronary artery; restenotic lesion must have been treated with a standard PTCA only. 3. Target lesion must be in major coronary artery or branch (target vessel). 4. Target lesion must have angiographic evidence of = 50% and < 100% stenosis (by operator visual estimate). If the target lesion is < 70% stenosed, there should be clinical evidence of ischemia. 5. Target vessel must have a Thrombolysis In Myocardial Infarction (TIMI) flow > 1. 6. Target lesion must be = 36 mm in length by operator visual estimate. 7. Target vessel must have a reference vessel diameter of 2.25-4.0 mm by operator visual estimate. 8. Target lesion must have been treated with a maximum of two overlapping stents. Exclusion Criteria: 1. Subject had clinical symptoms and/or electrocardiogram (ECG) changes consistent with acute ST elevation MI (STEMI) within 72 hours prior to the index procedure. 2. Subject is pregnant and/or breastfeeding or intends to become pregnant during the duration of the study. 3. Subject has a known allergy to contrast medium that cannot be adequately pre-medicated, or any known allergy to thienopyridine, aspirin, both heparin and bivalirudin, L-605 cobalt-chromium (Co-Cr) alloy or one of its major elements (cobalt, chromium, tungsten and nickel), silicon carbide, PLLA, sirolimus. 4. Revascularization of any target vessel within 9 months prior to the index procedure or previous PCI of any non-target vessel within 30 days prior to the index procedure or any PCI planned within the next 1 year. 5. Presence of an untreated clinically significant stenosis post-procedure whether treatment is planned or not. 6. Planned surgery within 6 months of index procedure unless DAPT can be maintained throughout the peri-surgical period. 7. History of a stroke or transient ischemic attack (TIA) within 6 months prior to the index procedure. 8. Subject has documented LVEF < 30% prior to consent. 9. Subject is dialysis-dependent. 10. Subject has impaired renal function (blood creatinine > 2.5 mg/dL or 221 µmol/L prior to the index procedure). 11. Subject has leukopenia (i.e. < 3,000 white blood cells/mm3), thrombocytopenia (i.e. < 100,000 platelets/mm3) or thrombocytosis (i.e. > 700,000 platelet/mm3). 12. Any significant concurrent medical diagnosis that would potentially impact DAPT effectiveness or increase thrombotic risk. 13. Subject is receiving chronic anticoagulation (e.g. coumadin, dabigatran, apixaban, rivaroxaban or any other agent). 14. Subject has life expectancy of < 1 year. 15. Subject is participating in an investigational (medical device or drug) clinical study. Subjects may be concurrently enrolled in a post-market study, as long as the post-market study device, drug or protocol does not interfere with the follow-up requirements of this study or does not involve a drug that may confound the interpretation of any relevant clinical events of interest (e.g. investigational DAPT therapy). 16. In the investigator's opinion, subject will not be able to comply with the follow-up requirements. Subjects will be excluded from the trial if any of the target lesions/vessels met any of the following angiographic criteria during the index procedure: 1. Target lesion was located within or treated through a saphenous vein graft or arterial graft. 2. Target lesion was a restenotic lesion that was previously treated with a bare metal or drug-eluting stent (in-stent restenosis). 3. Target lesion had any of the following characteristics: 1. Lesion location is within the left main coronary artery, or within 3 mm of the origin of the left anterior descending (LAD) or left circumflex (LCX). 2. Involves a side branch of > 2.0 mm in diameter. 4. Target vessel/lesion was excessively tortuous/angulated or is severely calcified, that would prevent complete inflation of an angioplasty balloon. This assessment should be based on visual estimation. 5. Target vessel had angiographic evidence of thrombus. 6. Target lesion was totally occluded (100% stenosis). 7. Target vessel was treated with brachytherapy any time prior to the index procedure. |
Country | Name | City | State |
---|---|---|---|
United States | AnMed Health | Anderson | South Carolina |
United States | University of Michigan Medical Center | Ann Arbor | Michigan |
United States | Piedmont Heart Institute | Atlanta | Georgia |
United States | Austin Heart | Austin | Texas |
United States | Seton Medical Center Austin | Austin | Texas |
United States | MedStar Union Memorial Hospital | Baltimore | Maryland |
United States | Northern Light Cardiology | Bangor | Maine |
United States | Brigham and Women's Hospital | Boston | Massachusetts |
United States | Massachusetts General Hospital | Boston | Massachusetts |
United States | Maimonides Medical Center | Brooklyn | New York |
United States | Penn State Health Holy Spirit Medical Center | Camp Hill | Pennsylvania |
United States | Charleston Area Medical Center Memorial Hospital | Charleston | West Virginia |
United States | University of Virginia Health System | Charlottesville | Virginia |
United States | University of Chicago Medical Center | Chicago | Illinois |
United States | University of Illinois | Chicago | Illinois |
United States | John Muir Medical Center | Concord | California |
United States | Baylor Heart and Vascular Hospital | Dallas | Texas |
United States | Cardiology Associates of Mobile | Fairhope | Alabama |
United States | UT Health Science Center | Houston | Texas |
United States | Ascension St. Vincent Medical Group | Indianapolis | Indiana |
United States | University of Kentucky | Lexington | Kentucky |
United States | Minneapolis Heart Institute | Minneapolis | Minnesota |
United States | Vanderbilt University Medical Center | Nashville | Tennessee |
United States | Columbia University Medical Center | New York | New York |
United States | Weill Cornell Medical College | New York | New York |
United States | Saint Michael's Medical Center | Newark | New Jersey |
United States | St. Joseph Hospital Orange | Orange | California |
United States | Advocate Lutheran General Hospital | Park Ridge | Illinois |
United States | Baystate Medical Center | Springfield | Massachusetts |
United States | AdventHealth Tampa | Tampa | Florida |
United States | Mercy Health - St Vincent Medical Center | Toledo | Ohio |
United States | MedStar Washington Hospital Center | Washington | District of Columbia |
United States | Ascension Via Christi Hospitals | Wichita | Kansas |
Lead Sponsor | Collaborator |
---|---|
Biotronik, Inc. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Percentage of Participants With Target Lesion Failure (TLF) at 12 Months Post-Index Procedure | TLF is defined as all cardiac death, target vessel Q-wave or non-Q-wave myocardial infarction (MI), or clinically driven target lesion revascularization (TLR). | 12-Months | |
Secondary | All-cause Death | at Hospital Discharge an average of 1 day, at 1 Month, at 1 Year | ||
Secondary | Protocol-defined Any-vessel Myocardial Infarction | at Hospital Discharge an average of 1 day, at 1 Month, at 1 Year | ||
Secondary | Target Lesion Revascularization (TLR) | at Hospital Discharge an average of 1 day, at 1 Month, at 1 Year | ||
Secondary | Target Vessel Revascularization (TVR) | at Hospital Discharge an average of 1 day, at 1 Month, at 1 Year | ||
Secondary | Cardiac Death or Protocol-defined Any-vessel MI | at Hospital Discharge an average of 1 day, at 1 Month, at 1 Year | ||
Secondary | Target Lesion Failure (Cardiac Death, Protocol-defined Target Vessel MI, Clinically-driven TLR) | at Hospital Discharge an average of 1 day, at 1 Month, at 1 Year | ||
Secondary | Target Vessel Failure (Cardiac Death, Protocol-defined Target Vessel MI, Clinically-driven TVR) | at Hospital Discharge an average of 1 day, at 1 Month, at 1 Year | ||
Secondary | MACE (Death, Protocol-defined Any Vessel Q Wave or Non-Q Wave MI, Clinically-driven TLR | at Hospital Discharge an average of 1 day, at 1 Month, at 1 Year | ||
Secondary | Stent Thrombosis | at 24 Hours, at 1 Month, at 1 Year | ||
Secondary | Number of Lesions With Device Success | Defined as attainment of < 30% residual stenosis of the target lesion using the assigned study stent only. | at Hospital Discharge an average of 1 day | |
Secondary | Number of Lesions With Lesion Success | Defined as attainment of < 30% residual stenosis of the target lesion using any percutaneous method. | at Hospital Discharge an average of 1 day | |
Secondary | Number of Participants With Procedure Success | Defined as attainment of < 30% residual stenosis of the target lesion using the assigned study stent only without occurrence of in-hospital major adverse cardiac events (MACE; composite of all-cause death, Q-wave or non-Q-wave MI, and any clinically-driven TLR). | at Hospital Discharge an average of 1 day |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06030596 -
SPECT Myocardial Blood Flow Quantification for Diagnosis of Ischemic Heart Disease Determined by Fraction Flow Reserve
|
||
Completed |
NCT04080700 -
Korean Prospective Registry for Evaluating the Safety and Efficacy of Distal Radial Approach (KODRA)
|
||
Recruiting |
NCT03810599 -
Patient-reported Outcomes in the Bergen Early Cardiac Rehabilitation Study
|
N/A | |
Recruiting |
NCT06002932 -
Comparison of PROVISIONal 1-stent Strategy With DEB Versus Planned 2-stent Strategy in Coronary Bifurcation Lesions.
|
N/A | |
Not yet recruiting |
NCT06032572 -
Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE)
|
N/A | |
Recruiting |
NCT05308719 -
Nasal Oxygen Therapy After Cardiac Surgery
|
N/A | |
Recruiting |
NCT04242134 -
Drug-coating Balloon Angioplasties for True Coronary Bifurcation Lesions
|
N/A | |
Completed |
NCT04556994 -
Phase 1 Cardiac Rehabilitation With and Without Lower Limb Paddling Effects in Post CABG Patients.
|
N/A | |
Recruiting |
NCT05846893 -
Drug-Coated Balloon vs. Drug-Eluting Stent for Clinical Outcomes in Patients With Large Coronary Artery Disease
|
N/A | |
Recruiting |
NCT06027788 -
CTSN Embolic Protection Trial
|
N/A | |
Recruiting |
NCT05023629 -
STunning After Balloon Occlusion
|
N/A | |
Completed |
NCT04941560 -
Assessing the Association Between Multi-dimension Facial Characteristics and Coronary Artery Diseases
|
||
Completed |
NCT04006288 -
Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease
|
Phase 4 | |
Completed |
NCT01860274 -
Meshed Vein Graft Patency Trial - VEST
|
N/A | |
Recruiting |
NCT06174090 -
The Effect of Video Education on Pain, Anxiety and Knowledge Levels of Coronary Bypass Graft Surgery Patients
|
N/A | |
Completed |
NCT03968809 -
Role of Cardioflux in Predicting Coronary Artery Disease (CAD) Outcomes
|
||
Terminated |
NCT03959072 -
Cardiac Cath Lab Staff Radiation Exposure
|
||
Recruiting |
NCT05065073 -
Iso-Osmolar vs. Low-Osmolar Contrast Agents for Optical Coherence Tomography
|
Phase 4 | |
Recruiting |
NCT04566497 -
Assessment of Adverse Outcome in Asymptomatic Patients With Prior Coronary Revascularization Who Have a Systematic Stress Testing Strategy Or a Non-testing Strategy During Long-term Follow-up.
|
N/A | |
Completed |
NCT05096442 -
Compare the Safety and Efficacy of Genoss® DCB and SeQuent® Please NEO in Korean Patients With Coronary De Novo Lesions
|
N/A |